Tuesday, November 13, 2018 5:13:00 PM
As a result, the total public offering size was 1,385,750 shares of common stock, and the gross proceeds from the public offering were approximately $5.4 million, before deducting underwriting discounts and offering expenses.
"On the heels of our recent Investigational Testing Authorization to commence human studies with our Thermo-Acoustic Enhanced Ultrasound, or TAEUS™, clinical system and the recent demand from institutional investors, we strategically raised the necessary capital to clean up our balance sheet and extend our financial runway," said Francois Michelon, CEO of ENDRA Life Sciences.
"Furthermore, we now have no debt outstanding and are confident that, with over $8.5 million recently added to the balance sheet and transformative milestones on the horizon, any near-term dilution risk is behind the company. We look forward to executing on our near-term commercial objectives," concluded Michelon.
Recent NDRA News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/16/2024 09:28:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 09:09:43 PM
- ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements • Business Wire • 08/28/2024 08:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:06:08 PM
- ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update • Business Wire • 08/22/2024 08:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:10:30 PM
- ENDRA Life Sciences Announces Reverse Stock Split • Business Wire • 08/16/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 09:00:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:06:44 PM
- ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024 • Business Wire • 08/13/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 01:24:59 PM
- ENDRA Life Sciences Announces Leadership Changes • Business Wire • 08/13/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 12:02:42 PM
- ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14 • Business Wire • 08/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:16:45 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/14/2024 08:01:26 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/14/2024 12:00:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:00:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/05/2024 04:15:12 AM
- ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering • Business Wire • 06/04/2024 01:21:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM